{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T13:04:52Z","timestamp":1789563892061,"version":"build-2803163510"},"reference-count":50,"publisher":"Wiley","issue":"8","license":[{"start":{"date-parts":[[2026,8,16]],"date-time":"2026-08-16T00:00:00Z","timestamp":1786838400000},"content-version":"vor","delay-in-days":15,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Cancer Reports"],"published-print":{"date-parts":[[2026,8]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background and Aims<\/jats:title>\n                    <jats:p>Acute myeloid leukemia (AML) remains the most common cause of death in adults with acute leukemia. Tyrosine kinase inhibitors (TKIs) have shown significant clinical efficacy in defined patient subgroups. Real\u2010world outcomes of AML patients undergoing TKI therapy have not been widely reported.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>In this real\u2010world retrospective study, we included 482 adult patients with AML treated with a TKI targeting FLT3, IDH1, or IDH2 from January 1, 2015, to December 31, 2023, in the countrywide Flatiron Health electronic health record\u2010derived deidentified database. We utilized unadjusted Kaplan\u2013Meier methods to calculate median real\u2010world event\u2010free survival (rwEFS) and overall survival (rwOS). We utilized a multivariable Cox regression model to evaluate characteristics associated with rwOS, modeling post\u2010TKI stem cell transplant (SCT) as a time\u2010varying covariate.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Those who received treatment at 1L (first\u2010line) and 2L+ (second\u2010line and beyond) had similar length of TKI therapy (3.7 vs. 3.4\u2009months), rwEFS (2.2 vs. 2.5\u2009months), and rwOS (12.3 vs. 13.1\u2009months), respectively. Among all patients, greater rwOS was associated with receiving pre\u2010TKI SCT (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001), commercial insurance (vs. Medicaid;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.035), younger age (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.043), and favorable 2017 ELN risk classification (vs. adverse;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.032). When restricted to patients treated with TKI at 2L+ without prior SCT, rwEFS were 1.4, 1.6, and 2.1\u2009months by targetable mutation (IDH2, IDH1, and FLT3), and rwOS were 8.7, 15.4, and 9.5\u2009months, respectively.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Patients treated with HMA plus TKI did not have significant differences compared to TKI alone. In this substantial, real\u2010world cohort of AML patients receiving TKIs, clinical outcomes remained deficient irrespective of timing of TKI start, mutational target, and concurrent HMA.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/cnr2.70657","type":"journal-article","created":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T04:06:14Z","timestamp":1786939574000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Real\u2010World Outcomes of Acute Myeloid Leukemia Patients Undergoing Treatment With Tyrosine Kinase Inhibitor (TKI) Therapy Targeting FLT3, IDH1, or IDH2"],"prefix":"10.1002","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7906-8782","authenticated-orcid":false,"given":"Manuel R.","family":"Espinoza\u2010Gutarra","sequence":"first","affiliation":[{"name":"The University of Alabama at Birmingham O'Neal Comprehensive Cancer Center  Birmingham Alabama USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2966-3521","authenticated-orcid":false,"given":"Brooke","family":"Jarret","sequence":"additional","affiliation":[{"name":"Flatiron Health  New York New York USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5184-2935","authenticated-orcid":false,"given":"Xiaoliang","family":"Wang","sequence":"additional","affiliation":[{"name":"Flatiron Health  New York New York USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anosheh","family":"Afghahi","sequence":"additional","affiliation":[{"name":"Flatiron Health  New York New York USA"},{"name":"University of Colorado School of Medicine  Aurora Colorado USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9982-3223","authenticated-orcid":false,"given":"Sejong","family":"Bae","sequence":"additional","affiliation":[{"name":"Wellstar MCG Health Medical Center  Augusta Georgia USA"},{"name":"Augusta University Georgia Cancer Center  Augusta Georgia USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,8,16]]},"reference":[{"key":"e_1_2_10_2_1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21871"},{"key":"e_1_2_10_3_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11864-023-01090-3"},{"key":"e_1_2_10_4_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-018-0357-9"},{"key":"e_1_2_10_5_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-021-00497-1"},{"key":"e_1_2_10_6_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1902688"},{"key":"e_1_2_10_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(17)30416-3"},{"key":"e_1_2_10_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtct.2022.12.006"},{"key":"e_1_2_10_9_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1716984"},{"key":"e_1_2_10_10_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2117344"},{"key":"e_1_2_10_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(22)00292-7"},{"key":"e_1_2_10_12_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-04-779405"},{"key":"e_1_2_10_13_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2021014901"},{"key":"e_1_2_10_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2022.106946"},{"key":"e_1_2_10_15_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-021-00604-2"},{"key":"e_1_2_10_16_1","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2023.0025"},{"key":"e_1_2_10_17_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2024025409"},{"key":"e_1_2_10_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2025.106031"},{"issue":"1","key":"e_1_2_10_19_1","doi-asserted-by":"crossref","first-page":"228","DOI":"10.3324\/haematol.2024.285768","article-title":"Comparing the Clinical Trial Efficacy Versus Real\u2010World Effectiveness of Treatments for Multiple Myeloma: A Population\u2010Based Study","volume":"110","author":"Visram A.","year":"2025","journal-title":"Haematologica"},{"key":"e_1_2_10_20_1","article-title":"Health Disparities in Acute Myeloid Leukemia Patients Undergoing Treatment With Tyrosine Kinase Inhibitor (TKI) Therapy Targeting FLT3, IDH1, or IDH2","volume":"16","author":"Espinoza\u2010Gutarra M. R.","year":"2026","journal-title":"Blood and Lymphatic Cancer"},{"key":"e_1_2_10_21_1","volume-title":"Comparison of Population Characteristics in Real\u2010World Clinical Oncology Databases in the US: Flatiron Health, SEER, and NPCR","author":"Ma X.","year":"2020"},{"key":"e_1_2_10_22_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-08-733196"},{"key":"e_1_2_10_23_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2003.04.036"},{"key":"e_1_2_10_24_1","unstructured":"FDA Oncology Center of Excellence Center for Drug Evaluation and Research Center for Biologics Evaluation and Research \u201cAcute Myeloid Leukemia: Developing Drugs and Biological Products for Treatment Guidance for Industry \u201d2022 cited November 2 2026 FDA\u20102020\u2010D\u20101298 https:\/\/www.fda.gov\/regulatory\u2010information\/search\u2010fda\u2010guidance\u2010documents\/acute\u2010myeloid\u2010leukemia\u2010developing\u2010drugs\u2010and\u2010biological\u2010products\u2010treatment\u20100."},{"key":"e_1_2_10_25_1","doi-asserted-by":"publisher","DOI":"10.1111\/1475-6773.13669"},{"key":"e_1_2_10_26_1","volume-title":"R: A Language and Environment for Statistical Computing","author":"R Development Core Team","year":"2026"},{"key":"e_1_2_10_27_1","volume-title":"survminer: Drawing Survival Curves using \u2018ggplot2\u2019: R Package Version 0.4.9","author":"Kassambara A.","year":"2021"},{"key":"e_1_2_10_28_1","volume-title":"Modeling Survival Data: Extending the Cox Model","author":"Grambsch P.","year":"2020"},{"key":"e_1_2_10_29_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2012.066100"},{"key":"e_1_2_10_30_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-021-01229-x"},{"key":"e_1_2_10_31_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.18290"},{"key":"e_1_2_10_32_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2017.02.001"},{"key":"e_1_2_10_33_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2023.107326"},{"key":"e_1_2_10_34_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2021011103"},{"key":"e_1_2_10_35_1","doi-asserted-by":"publisher","DOI":"10.1186\/s40364-020-00208-1"},{"issue":"4","key":"e_1_2_10_36_1","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.3324\/haematol.2023.283606","article-title":"Prognostic Value of European Leukemia Net 2022 Criteria and Genomic Clusters Using Machine Learning in Older Adults With Acute Myeloid Leukemia","volume":"109","author":"Park S.","year":"2024","journal-title":"Haematologica"},{"key":"e_1_2_10_37_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2023-187060"},{"key":"e_1_2_10_38_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2019002140"},{"key":"e_1_2_10_39_1","unstructured":"FDA \u201cFDA Approves Venetoclax in Combination for AML in Adults \u201d2018 January 18 2025 https:\/\/www.fda.gov\/drugs\/fda\u2010approves\u2010venetoclax\u2010combination\u2010aml\u2010adults."},{"key":"e_1_2_10_40_1","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2022.2136952"},{"key":"e_1_2_10_41_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2023.107331"},{"key":"e_1_2_10_42_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2022.106942"},{"key":"e_1_2_10_43_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2021014586"},{"key":"e_1_2_10_44_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.01632"},{"key":"e_1_2_10_45_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2023.41.16_suppl.7012"},{"key":"e_1_2_10_46_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2023-173033"},{"key":"e_1_2_10_47_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(21)00494-0"},{"key":"e_1_2_10_48_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-21-3467"},{"key":"e_1_2_10_49_1","unstructured":"Goverment of Canada \u201cIDHIFA (Enasidenib Mesylate)\u2014Market Withdrawal and Continued Access \u201dJanuary 18 2025 https:\/\/recalls\u2010rappels.canada.ca\/en\/alert\u2010recall\/idhifa\u2010enasidenib\u2010mesylate\u2010market\u2010withdrawal\u2010and\u2010continued\u2010access."},{"key":"e_1_2_10_50_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.01548"},{"key":"e_1_2_10_51_1","doi-asserted-by":"publisher","DOI":"10.1080\/1120009X.2023.2247200"}],"container-title":["Cancer Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cnr2.70657","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/cnr2.70657","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cnr2.70657","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T12:16:37Z","timestamp":1789560997000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/cnr2.70657"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":50,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["10.1002\/cnr2.70657"],"URL":"https:\/\/doi.org\/10.1002\/cnr2.70657","archive":["Portico"],"relation":{},"ISSN":["2573-8348","2573-8348"],"issn-type":[{"value":"2573-8348","type":"print"},{"value":"2573-8348","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"2025-10-29","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-07-30","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-08-16","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e70657"}}